Medpace (NASDAQ:MEDP) Director Fred Davenport, Jr. Sells 7,283 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Fred Davenport, Jr. sold 7,283 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total value of $4,414,590.45. Following the completion of the transaction, the director directly owned 3,798 shares of the company’s stock, valued at approximately $2,302,157.70. This trade represents a 65.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Medpace Trading Up 1.3%

Shares of NASDAQ:MEDP opened at $620.75 on Friday. The firm has a market capitalization of $17.33 billion, a PE ratio of 36.39, a PEG ratio of 2.73 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90. The business’s 50 day moving average is $550.16 and its 200-day moving average is $492.71.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same period last year, the business earned $3.10 earnings per share. Medpace’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Medpace during the second quarter worth approximately $1,323,047,000. AQR Capital Management LLC grew its stake in shares of Medpace by 65.1% during the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares during the period. Madison Asset Management LLC acquired a new stake in shares of Medpace during the second quarter worth $128,956,000. Bank of America Corp DE bought a new stake in Medpace in the second quarter valued at about $116,891,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Medpace by 205.8% in the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MEDP. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Barclays set a $600.00 price target on Medpace in a research note on Thursday, July 23rd. Mizuho increased their price objective on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. TD Cowen increased their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Finally, Truist Financial upped their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.